laitimes

Changchun Gaoxin talked about "growth hormone collection": research and formulate a plan, there is no specific expectation

author:The Paper

The Paper's reporter Li Xiaoxiao

On January 19, Changchun High-tech (000661) responded on the interactive platform on the "growth hormone products into the collection" that the website of the Guangdong Provincial Drug Exchange Center today announced the relevant centralized procurement documents, the company is currently actively studying policy provisions and will reasonably formulate a plan, there is no specific impact of the expectations.

On January 19, the Guangdong Provincial Drug Trading Center issued the notice of "Guangdong Alliance Diclofenac and Other Drugs Centralized Procurement Documents", carrying out the centralized procurement of 276 drug alliance areas such as diclofenac, and participating in the alliance involving 11 provinces and regions, including Guangdong, Shanxi, Jiangxi, Henan, Guangxi, Hainan, Guizhou, Qinghai, Ningxia, Xinjiang, xinjiang and Xinjiang Production and Construction Corps.

The above 276 drugs include high-margin growth hormone, which is the first time it has entered the collection from public information. Judging from the published list, there are 20 drug names involved, and the companies behind them include Novo Nordisk, LG Life Sciences of South Korea, Kinsey Pharmaceutical, Anke Biological, Shanghai United Sail Biological, Zhongshan Weiming Haiji Biological and other 6 enterprises.

Kinsey Pharmaceutical is a high-tech subsidiary of Changchun, and its main business is growth hormone. According to IQVIA and Guoyuan Securities data, in 2020, Kinsey Pharmaceutical will occupy 78.39% of the market share in the domestic growth hormone drug field.

Or affected by the above news, Changchun High-tech fell to a stop today, at 227.6 yuan, and the market value fell below 100 billion to 92.11 billion yuan.

Responsible Editor: Yes Dong Dong Photo Editor: Hu Mengxi

Proofreader: Luan Meng

Read on